Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Obstetrics & Gynecology 1983;62:502-505
© 1983 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FUGERE, P.
Right arrow Articles by CARON, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FUGERE, P.
Right arrow Articles by CARON, M.

Single Oral Dose of Ornidazole in Women With Vaginal Trichomoniasis

PIERRE FUGERE, MD, GUY VERSCHELDEN, MD and MICHEL CARON, MSc

From the University of Montreal, Department of Obstetrics & Gynecology, Hôpital Saint-Luc, Montreal; and Department of Clinical Research, Hoffmann-La Roche Limited, Vaudreuil, Québec, Canada.

Fifty-nine women with trichomonal vaginitis were randomly allocated to receive treatment with a single oral dose of either 0.5, 1.0, or 1.5 g of ornidazole. One week after treatment, a parasitologic cure was observed in 100% of patients treated with 1.5 g, in 95% of patients treated with 1.0 g, and in 65% of patients given 0.5 g. At the one-month follow-up visit, the cure rate remained at 100% for the 1.5-g dose group but dropped to 85 and 45% in the 1.0– and 0.5-g dose groups, respectively. The disappearance of symptomatic complaints was also dose related: the clinical cure was 100, 85, and 40% at the first follow-up visit and 89, 80, and 30% at the second follow-up visit. Adverse effects of mild or moderate severity were reported by 13 patients. These were encountered mostly in the 1.5– and the 1.0-g dose groups. The most frequent adverse effects were dizziness and gastrointestinal distress. Laboratory safety test did not reveal any significant toxicity. This study confirms that single-dose treatment of trichomoniasis with an oral dose of 1.5 or 1.0 g of ornidazole is effective and well tolerated.




This article has been cited by other articles:


Home page
Clin. Microbiol. Rev.Home page
D. Petrin, K. Delgaty, R. Bhatt, and G. Garber
Clinical and Microbiological Aspects of Trichomonas vaginalis
Clin. Microbiol. Rev., April 1, 1998; 11(2): 300 - 317.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by the American College of Obstetricians and Gynecologists.